Climb Bio, Inc. Board of Directors

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Dr. Brett Kaplan M.B.A., M.D.

Dr. Brett Kaplan M.B.A., M.D.

COO & Principal Financial Officer

Dr. Nishi Rampal M.D.

Dr. Nishi Rampal M.D.

Senior Vice President of Clinical Development

Ms. Emily Pimblett

Ms. Emily Pimblett

Chief Accounting Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.